Ocugen Highlights Modifier Gene Therapy Platform at Cell & Gene Meeting on the Mesa
Key Insights
Ocugen's CEO, Dr. Shankar Musunuri, presented the company's modifier gene therapy platform at the 2024 Cell & Gene Meeting on the Mesa.
The presentation included updates on OCU400 for retinitis pigmentosa (search) (Phase 3), OCU410 for geographic atrophy (search) (Phase 2), and OCU410ST for Stargardt disease (search) (Phase 1/2).
Ocugen remains on track for a 2026 BLA and MAA approval target for OCU400, with Phase 3 dosing currently underway.
Ocugen, Inc. showcased its innovative modifier gene therapy platform at the 2024 Cell & Gene Meeting on the Mesa, with Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder, providing an overview of their clinical programs. The presentation highlighted the potential of Ocugen's therapies to address significant unmet needs in inherited retinal diseases.
Clinical Program Updates
Dr. Musunuri detailed the progress of three key clinical trials:
- OCU400 (Phase 3 liMeliGhT): This gene therapy is being evaluated for the treatment of retinitis pigmentosa (RP), a group of genetic disorders that cause progressive vision loss. The Phase 3 liMeliGhT trial is currently enrolling patients, and Ocugen anticipates a Biologics License Application (BLA) and Marketing Authorization Application (MAA) submission in 2026.
- OCU410 (Phase 2 ArMaDa): OCU410 is under investigation for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The ArMaDa Phase 2 trial is designed to assess the safety and efficacy of OCU410 in patients with GA.
- OCU410ST (Phase 1/2 GARDian): This gene therapy is in early-stage development for Stargardt disease, a genetic form of macular degeneration that affects children and young adults. The GARDian Phase 1/2 trial is evaluating the safety and preliminary efficacy of OCU410ST.
Modifier Gene Therapy Platform
Ocugen's modifier gene therapy platform aims to address multiple retinal diseases with a single product. This approach targets common disease pathways, potentially offering a broader therapeutic benefit compared to traditional gene therapies that address only specific genetic mutations.
Meeting on the Mesa
The Cell & Gene Meeting on the Mesa is a prominent industry event that brings together decision-makers to discuss the latest advancements in cell and gene therapies. According to Dr. Musunuri, the meeting is crucial for translating cutting-edge science into effective treatment options, especially where no treatment options exist. The Alliance for Regenerative Medicine supports advanced therapies, and this gathering reflects the organization’s impact in advocating for patients, healthcare systems, and society.
In addition to the presentation, Ocugen's executive team engaged in one-on-one meetings to further showcase the company's business and clinical development strategy.